2Pediatric Hematology of Erciyes University, Kayseri – Turkey
3Department of Nuclear Medicine, Erciyes University Faculty of Medicine, Kayseri, Turkey
4Department of Pediatrics, Erciyes University Medical Faculty, Kayseri, Turkey
Abstract
Purpose: In this study, we determined osteoporosis by Dual Energy X-Ray (DXA) and the effectiveness of pamidronate treatment in 24 thalassaemic patients in the Pediatric Hematology Unit of Erciyes University.
Materials and Methods: Twenty-four thalassaemic patients with an age range of 6-22 years (14 girl, 10 boy, mean age: 11.20 ± 3,9) were included in the study. Bone mineral densities of lumbar vertebrae L1-L4 and femur neck were measured by DXA method. Z score of bone mineral densities of vertebrae L1-L4 was below -2.5 in 9 patients (37.5 %), -1 to -2.5 in 14 patients (58.3%) and was normal in one patient. Pamidronate treatment (15 mg/dose for patients at age 15 below, 30 mg/dose at age above 15, per three months for one year) was given to 23 osteoporotic (Z score below -2,5) and osteopenic (Z score -1 to -2,5) patients with bone pain and history of bone fracture.
Results: The mean Z score of L1-L4 was -2.34 ± 0.77 (Mean BMD: 0.555 ± 0.106) at the beginning and -2.17 ± 0.88 (Mean BMD: 0.587 ± 0.107) after one year. There was a statistically significant difference between results of BMD at the beginning and after 12 months.
Conclusion: Pamidronate treatment is effective in thalassaemia-induced osteoporosis.
2Pediatric Hematology of Erciyes University, Kayseri – Turkey
3Department of Nuclear Medicine, Erciyes University Faculty of Medicine, Kayseri, Turkey
4Department of Pediatrics, Erciyes University Medical Faculty, Kayseri, Turkey
Amaç: Bu çalışmada Erciyes Üniversitesi Pediatrik Hematoloji bölümünce takip edilen 24 talasemik hastada pamidronate tedavisinin etkinliği Dual Energy X-Ray (DXA) yöntemi ile belirlenmiştir.
Gereç ve Yöntem: Bu çalışmaya yaşları 6-22 arasında (14 kız, 10 erkek, ortalama yaş: 11,20±3,9) 24 talasemik hasta dahil edildi. Lumbar L1-L4 vertebra ve femur boynu kemik mineral dansitesi (KMD) DXA yöntemi ile ölçüldü. Lumber L1-L4 vertebra KMD Z skoru 9 hastada -2,5 altında (%37,5), 14 hastada -1 ile -2,5 arası (%58,3) ve 1 hastada normal idi. Pamidronat tedavisi (15 yaşın altında 15mg/doz, 15 yaşın üstünde 30mg/doz, bir yıl süre ile üç ayda bir) osteoporotik (Z skoru -2,5 altında) ve kemik kırık hikayesi ve kemik ağrısı olan osteopenik 23 hastaya verildi.
Bulgular: L1-L4 vertebra başlangıçta ortalama Z skoru -2,34 ± 0,77 (ortalama KMD: 0,555 ± 0,106 ), bir yıl sonra Z skoru -2,17±0,88 (ortalama KMD: 0,587±0,107) idi. Başlangıç ve 12 ay sonraki KMD arasında istatistiksel olarak önemli fark vardı.
Sonuç: Pamidronat tedavisi talasemiye bağlı osteoporozda etkilidir.